API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
IBP-1016 (lactobacillus reuteri) is known to have four interactive mechanisms of action that is gut microbiome and receives FDA orphan drug designation for gastroschisis.
Lead Product(s): Lactobacillus Reuteri
Therapeutic Area: Pediatrics/Neonatology Product Name: IBP-1016
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 03, 2023
Details:
IBP-9414 (lactobacillus reuteri), is a human bacterial strain naturally present in breast milk. IBP-1016 is being developed for prevention of necrotizing entercolitis (NEC) and sustained feeding tolerance (SFT) among premature infants.
Lead Product(s): Lactobacillus Reuteri
Therapeutic Area: Gastroenterology Product Name: IBP-9414
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2023
Details:
IBP-9414 (lactobacillus reuteri), is a human bacterial strain naturally present in breast milk. IBP-1016 is being developed for prevention of Necrotizing Entercolitis (NEC) and sustained feeding tolerance (SFT) among premature infants.
Lead Product(s): Lactobacillus Reuteri
Therapeutic Area: Gastroenterology Product Name: IBP-9414
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2023
Details:
IBP-9414 for the prevention of necrotizing enterocolitis contains the active substance lactobacillus reuteri, known to be anti-inflammatory, anti-pathogenic and beneficial to gut motility. It is a co-evolved human bacterial strain naturally present in breast milk.
Lead Product(s): Lactobacillus Reuteri
Therapeutic Area: Gastroenterology Product Name: IBP-9414
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2023
Details:
IBP-9414 (lactobacillus reuteri), is a human bacterial strain naturally present in breast milk. IBP-1016 is being developed for gastroschisis (a severe and rare disease affecting infants), to prevent ROP and to prevent antibiotic resistant hospital acquired infections.
Lead Product(s): Lactobacillus Reuteri
Therapeutic Area: Gastroenterology Product Name: IBP-9414
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2023
Details:
Top-line results from the study demonstrated that SB-121 (Lactobacillus Reuteri), represents the first clinical validation of ABT platform was safe and well tolerated.
Lead Product(s): Lactobacillus Reuteri,Sephadex,Maltose
Therapeutic Area: Neurology Product Name: SB-121
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
IBP-9414 (lactobacillus Reuteri), strain-specific attributes which affect the NEC pathogenesis is world’s first approved probiotic drug with the goal to prevent life-threatening diseases in premature infants.
Lead Product(s): Lactobacillus Reuteri
Therapeutic Area: Gastroenterology Product Name: IBP-9414
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2022
Details:
IBT’s Clinical Phase III study of the drug candidate IBP-9414 for the prevention of necrotizing enterocolitis (NEC) and improvement of feeding tolerance in premature infants, the Connection Study.
Lead Product(s): Lactobacillus Reuteri
Therapeutic Area: Gastroenterology Product Name: IBP-9414
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2021
Details:
IBT is currently developing the drug candidate IBP-9414. IBP-9414 contains the active compound Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk.
Lead Product(s): Lactobacillus Reuteri
Therapeutic Area: Gastroenterology Product Name: IBP-9414
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2021
Details:
IBT is developing the drug candidate IBP-9414, contains the active substance Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk, for the prevention of necrotizing enterocolitis and improvement of feeding tolerance in premature infants.
Lead Product(s): Lactobacillus Reuteri
Therapeutic Area: Gastroenterology Product Name: IBP-9414
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2021
Details:
IBT is currently developing IBP-9414 to prevent necrotizing enterocolitis, and to improve feeding tolerance in premature infants. IBP-9414 contains Lactobacillus reuteri as an active ingredient, which is a human bacterial strain found naturally in breast milk.
Lead Product(s): Lactobacillus Reuteri
Therapeutic Area: Gastroenterology Product Name: IBP-9414
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 05, 2021